Teva Multiple-Sclerosis Treatment Meets Goals in New Dosing Regimen

Teva Pharmaceutical Industries said its multiple-sclerosis treatment administered three times a week reduced the annual relapse rate by more than 34 percent compared with a placebo in a one-year clinical trial.
Fox Business